Signaling Lymphocytic Activation Molecule Family

Type-I membrane glycoproteins that are expressed primarily on the surface of CD4 or CD8-positive T-CELLS; NATURAL KILLER CELLS; and some populations of B CELLS. They are characterized by an N-terminal, extracellular IMMUNOGLOBULIN-LIKE DOMAIN and a membrane-proximal IMMUNOGLOBULIN C2-SET DOMAIN. SLAMF receptors typically signal through homophilic interactions and are important for mediating the immune response and immune cell differentiation.

Also Known As:

Networked: 39 relevant articles (0 outcomes, 4 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Veillette, André: 4 articles (02/2016 - 05/2006)
2.	Bouhlal, Hicham: 3 articles (02/2022 - 05/2016)
3.	Marcq, Ingrid: 3 articles (02/2022 - 05/2016)
4.	Nguyen-Khac, Eric: 3 articles (02/2022 - 05/2016)
5.	Ishibashi, Mariko: 3 articles (01/2021 - 10/2018)
6.	Tamura, Hideto: 3 articles (01/2021 - 10/2018)
7.	Comte, Denis: 3 articles (01/2017 - 01/2016)
8.	Karampetsou, Maria P: 3 articles (01/2017 - 01/2016)
9.	Kis-Toth, Katalin: 3 articles (01/2017 - 01/2016)
10.	Kyttaris, Vasileios C: 3 articles (01/2017 - 01/2016)

Related Diseases

1.	Multiple Myeloma 01/13/2021 - "The signaling lymphocytic activation molecule (SLAM) family receptors are expressed on various immune cells and malignant plasma cells in multiple myeloma (MM) patients. " 01/13/2021 - "Immune Functions of Signaling Lymphocytic Activation Molecule Family Molecules in Multiple Myeloma." 07/01/2019 - "Expression analysis of two SLAM family receptors, SLAMF2 and SLAMF7, in patients with multiple myeloma." 10/01/2020 - "The signaling lymphocytic activation molecule family 3 (SLAMF3) is highly expressed on plasma cells from patients with multiple myeloma (MM) and induces high malignant potential by ERK signaling mediated via the interaction with adaptor proteins SHP2 and GRB2. " 10/05/2018 - "The signaling lymphocytic activation molecule family (SLAMF7; also known as CS1 or CD319) is highly expressed on plasma cells from multiple myeloma (MM) as well as natural killer (NK) cells and is a well-known therapeutic target of elotuzumab. "
2.	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/01/2017 - "Genome-wide linkage analysis studies (GWAS) studies in systemic lupus erythematosus (SLE) identified the 1q23 region on human chromosome 1, containing the Signaling Lymphocytic Activation Molecule Family (SLAMF) cluster of genes, as a lupus susceptibility locus. " 01/01/2017 - "Expression patterns of signaling lymphocytic activation molecule family members in peripheral blood mononuclear cell subsets in patients with systemic lupus erythematosus." 01/01/2017 - "Signaling Lymphocytic Activation Molecule Family Member 7 Engagement Restores Defective Effector CD8+ T Cell Function in Systemic Lupus Erythematosus." 01/01/2016 - "Selective Loss of Signaling Lymphocytic Activation Molecule Family Member 4-Positive CD8+ T Cells Contributes to the Decreased Cytotoxic Cell Activity in Systemic Lupus Erythematosus." 06/01/2010 - "Genes encoding SLAM family receptors are located at 1q23, implicated in systemic lupus erythematosus (SLE). "
3.	Infections 02/01/2013 - "Because signaling through Slam family receptors can affect innate immunity [natural killer T cell (NKT) and γ-δ T-cell receptor], and innate immunity can determine susceptibility to coxsackievirus B3 (CVB3) infection, the present study evaluated the response of C57Bl/6 and congenic B6.129c1 mice (expressing the 129-derived Slam locus) to CVB3. " 02/01/2021 - "bovis infection, there was increased expression of the lymphocyte activated genes basic leucine zipper transcription factor (BATF) and signaling lymphocytic activation molecule family members 1 and 7 (SLAMF 1 and SLAMF 7) in PBMCs compared with that in unstimulated cells. " 09/01/2020 - "Structural and functional analysis of the signaling lymphocytic activation molecule family 7 (SLAMF7) gene in response to infection with coagulase-negative and coagulase-positive staphylococci."
4.	Aplastic Anemia (Anemia, Hypoplastic) 01/01/2021 - "This study investigated the expression status of signaling lymphocytic activation molecule family 6 (SLAMF6) in CD8+ T lymphocytes of patients with severe aplastic anemia (SAA) and its association with the clinical indicators and immune status of the disease. "
5.	Neoplasms (Cancer) 01/01/2023 - "There is growing evidence that SLAM-family receptors have been involved in cancer progression and heralded as a novel immune checkpoint on T cells. " 01/01/2022 - "Signaling lymphocytic activation molecule family 7 (SLAMF7) suppresses cancer cell phagocytosis and is an ideal target under clinical development. " 08/30/2021 - "LY9 and SLAMF1 are classified as SLAM family receptors involved in the activation of hematopoietic cells and the pathogenesis of multiple malignancies. " 03/23/2018 - "Signaling lymphocytic activation molecules Slam and cancers: friends or foes?" 02/01/2016 - "Recent findings have provided new insights into the key roles of SLAM family receptors in normal immunity, their involvement in human diseases and their usefulness as drug targets to treat human malignancies. "

Related Drugs and Biologics

1.	elotuzumab
2.	T-Cell Antigen Receptors (T-Cell Receptor)
3.	Dexamethasone (Maxidex)
4.	Lenalidomide (CC 5013)
5.	Proteins (Proteins, Gene)
6.	Ligands
7.	Epiregulin
8.	Tetraspanins
9.	Folate Receptor 2
10.	Basic-Leucine Zipper Transcription Factors

Related Therapies and Procedures

1.	Immunotherapy
2.	Secondary Prevention
3.	Therapeutics